Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Functional relationship of serine 90 phosphorylation and the surrounding putative salt bridge in bovine prolactin.

Schenck EJ, Canfield JM, Brooks CL.

Mol Cell Endocrinol. 2003 Jun 30;204(1-2):117-25.

PMID:
12850287
2.

Mutation of serine 90 to glutamic acid mimics phosphorylation of bovine prolactin.

Maciejewski PM, Peterson FC, Anderson PJ, Brooks CL.

J Biol Chem. 1995 Nov 17;270(46):27661-5.

3.

Amino acids in the amino terminal region of the rat prolactin contribute to PRL-receptor binding and NB2 cell proliferation activity.

Maruyama O, Kato T, Wakabayashi K, Kato Y.

Biochem Biophys Res Commun. 1994 Nov 30;205(1):312-9.

PMID:
7999042
4.

Biological activity of phosphorylated and dephosphorylated bovine prolactin.

Wicks JR, Brooks CL.

Mol Cell Endocrinol. 1995 Aug 11;112(2):223-9.

PMID:
7489826
5.

Modification of arginine residues in ovine prolactin by 1,2-cyclohexanedione. Effect on binding capacity to lactogenic receptors.

Cymes GD, Atlasovich FM, Caridad JJ, Iglesias MM, Wolfenstein-Todel C.

Int J Pept Protein Res. 1994 Jul;44(1):31-5.

PMID:
7960402
8.

The functional consequences of mis-sense mutations affecting an intra-molecular salt bridge in arylsulphatase A.

Schestag F, Yaghootfam A, Habetha M, Poeppel P, Dietz F, Klein RA, Zlotogora J, Gieselmann V.

Biochem J. 2002 Oct 15;367(Pt 2):499-504.

9.

Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor.

Svensson LA, Bondensgaard K, Nørskov-Lauritsen L, Christensen L, Becker P, Andersen MD, Maltesen MJ, Rand KD, Breinholt J.

J Biol Chem. 2008 Jul 4;283(27):19085-94. doi: 10.1074/jbc.M801202200. Epub 2008 May 8.

10.
11.

Identification of HRPAP20: a novel phosphoprotein that enhances growth and survival in hormone-responsive tumor cells.

Karp CM, Pan H, Zhang M, Buckley DJ, Schuler LA, Buckley AR.

Cancer Res. 2004 Feb 1;64(3):1016-25.

12.

Phosphorylation of bovine prolactin eliminates luteotropic activity in the rat.

Brooks CL, Saiduddin S.

Life Sci. 1998;63(14):1281-7.

PMID:
9771916
13.

Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL.

Jomain JB, Tallet E, Broutin I, Hoos S, van Agthoven J, Ducruix A, Kelly PA, Kragelund BB, England P, Goffin V.

J Biol Chem. 2007 Nov 9;282(45):33118-31. Epub 2007 Sep 4.

14.

Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.

Huang Y, Li X, Jiang J, Frank SJ.

Oncogene. 2006 Dec 7;25(58):7565-76. Epub 2006 Jun 19.

PMID:
16785991
15.

Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation.

Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N, Raz A.

J Biol Chem. 2005 Mar 18;280(11):10419-26. Epub 2005 Jan 5.

16.

Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone.

Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM.

Endocrinology. 1998 Feb;139(2):609-16.

PMID:
9449632
17.

Dephosphorylation of Ser-226 facilitates plasma membrane retention of Ntcp.

Anwer MS, Gillin H, Mukhopadhyay S, Balasubramaniyan N, Suchy FJ, Ananthanarayanan M.

J Biol Chem. 2005 Sep 30;280(39):33687-92. Epub 2005 Jul 18.

18.

Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays.

Cárdenas-Mondragón G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leaños-Miranda A.

J Rheumatol. 2007 Jul;34(7):1514-21. Epub 2007 May 15.

PMID:
17516622
19.

Supplemental Content

Support Center